Phathom Pharmaceuticals Inc. (NASDAQ:PHAT) shares are trading higher Friday after the company announced a major regulatory win. What To Know: The FDA has granted 10-year new chemical entity ...
Phathom Pharmaceuticals stock has significantly declined since 2021, despite securing FDA approval for Vonoprazan to treat H. pylori infection and GERD. The company faced delays in launching its ...
How Do I Take Voquezna? Voquezna is an oral tablet that is taken once daily for GERD or erosive esophagitis and twice daily for H. pylori. Voquezna can be taken with or without food. Your doctor will ...
Phathom Pharmaceuticals, Inc. has secured 10 years of FDA exclusivity for Voquezna in GERD, boosting its stock and providing critical regulatory protection until 2032. Despite this win, Voquezna's U.S ...
FLORHAM PARK, N.J., May 15, 2024 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for ...
VOQUEZNA, the first and only FDA-approved potassium-competitive acid blocker (PCAB), is now available through major retail pharmacies and BlinkRx, an end-to-end digital fulfillment channel VOQUEZNA ...
CVS Caremark, the largest pharmacy benefit manager (PBM) in the United States, added VOQUEZNA ® (vonoprazan) tablets to its national formularies for its more than 26 million commercially insured ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results